Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

Core Viewpoint - Organogenesis Holdings Inc. supports the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes, emphasizing the need for payment rates to reflect clinical value and relative cost [1][2]. Company Overview - Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing, manufacturing, and commercializing solutions for advanced wound care and surgical and sports medicine markets [3][5]. - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3][5]. Industry Context - The proposed payment structure by CMS aims to establish a per centimeter square payment methodology based on FDA classification for skin substitutes, which is expected to reduce Medicare spending and ensure consistent payment across care settings [2]. - The new payment approach is anticipated to enhance access to innovative wound healing technologies, which have been shown to reduce life-threatening amputations and complications [2]. Future Outlook - With over forty years of leadership in regenerative medicine, the company is well-positioned for growth in the evolving wound care market [2]. - The company remains committed to collaborating with CMS and other stakeholders to refine proposed policies that promote long-term stability and expand access to PMA products [2].